Science and technology in Russia

RDIF: Laboratorios Richmond to provide Argentina with over 3 million doses of the second component of the Sputnik V vaccine in August with the first 150,000 doses to become available for vaccination this week

Retrieved on:

Tuesday, August 3, 2021

Adenoviridae, Clinical trials, Vaccine controversies, Medicine, Gamaleya Research Institute of Epidemiology and Microbiology, Science and technology in Russia, Sputnik V COVID-19 vaccine, Vaccination, Health sciences, COVID-19 vaccination in Vietnam, COVID-19 vaccination in Algeria

Laboratorios Richmond is expected to produce over 3 million doses of the second component of Sputnik V in August.

Key Points:

Laboratorios Richmond is expected to produce over 3 million doses of the second component of Sputnik V in August.
This week the Company will start supplying the Government of Argentina with locally produced Sputnik V vaccine including 150,000 doses of the second component to protect the population.
Argentina was the first country in Latin America both to authorize Sputnik V and to start its production.
To date, the Sputnik V vaccine has been registered in 69 countries globally with a total population of over 3.7 bn people.

Swedish company ZandCell offers Russia 750 million dose vaccine capacity for Sputnik V and Aurora

Retrieved on:

Thursday, July 29, 2021

COVID-19 pandemic in Russia, COVID-19 vaccines, Clinical trials, Medicine, Gamaleya Research Institute of Epidemiology and Microbiology, Science and technology in Russia, Vaccination, Sputnik V COVID-19 vaccine, Mass media, Sputnik, COVID-19 vaccine, COVID-19 vaccination in India

"We want either Sputnik V vaccine from Gamaleya or Aurora from Vector Institute.

Key Points:

"We want either Sputnik V vaccine from Gamaleya or Aurora from Vector Institute.
I believe Sputnik V is the best vaccine in the world right now.
We are ready to manufacture 750 million doses per year and we offer our capacity to Russia.
For more information on ZandCell email: [email protected]
Please visit the company's website at ZandCell.com or follow @ZandCell on Twitter.

DGAP-News: T&T Group: Vietnam Government supports T&T Group in purchase of 40 million Sputnik V vaccine doses

Retrieved on:

Thursday, July 22, 2021

COVID-19 pandemic in Russia, Medicine, COVID-19, Science and technology in Russia, Sputnik V COVID-19 vaccine, COVID-19 vaccine, Vaccination, COVID-19 vaccination in Albania, COVID-19 vaccination in Vietnam

HANOI, VIETNAM - Media OutReach - 22 July 2021 - On July 12, the Government of Vietnam issued Resolution No.

Key Points:

HANOI, VIETNAM - Media OutReach - 22 July 2021 - On July 12, the Government of Vietnam issued Resolution No.
73/NQ-CP allowing T&T Group to purchase Sputnik V vaccines from the Russian Federation without using funds from the State budget or Vietnam's COVID-19 Vaccine Fund.
The Government's resolution stated that, at the request of the vaccine manufacturer, the Government agreed to a proposal from the Ministry of Health to sign an agreement that relinquishes liability for the use of the Sputnik V vaccine.
Implementing the Government's resolution, the Ministry of Health sent an official dispatch to the Russian Direct Investment Fund (RDIF) to introduce them to the T&T Group to negotiate to buy 40 million doses of the Sputnik V vaccine.

Sputnik V vaccine elicits high IGG antibodies and neutralizing antibodies titers, a study in Argentina published in international Cell Reports Medicine journal shows

Retrieved on:

Monday, July 12, 2021

COVID-19 vaccines, Vaccines, Clinical trials, Vaccination, Medicine, COVID-19 pandemic in Russia, Science and technology in Russia, Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V COVID-19 vaccine, Sputnik Light, COVID-19, Immunoglobulin G

The study has been published in an international peer-reviewed, open access Cell Reports Medicine journal: https://www.sciencedirect.com/science/article/pii/S2666379121002081

Key Points:

The study has been published in an international peer-reviewed, open access Cell Reports Medicine journal: https://www.sciencedirect.com/science/article/pii/S2666379121002081
The research evaluates SARS-CoV-2-specific antibody responses after vaccination of 288 healthcare workers with Sputnik V in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses among non-infected and previously infected individuals.
Among key findings in the article they note that the first dose of Sputnik V induced strong immune response in 94% of individuals previously not infected with COVID.
In authors' opinion, vaccination with only the first component of Sputnik V (Sputnik Light vaccine) is sufficient to protect previously infected individuals.
To date, Sputnik V has been registered in 67 countries globally with a total population of over 3.5 billion people.

CytoImmune Therapeutics Welcomes Aleksey Krylov, Chief Financial Officer

Retrieved on:

Thursday, June 24, 2021

Russian scientists, Chief financial officer, Science and technology in Russia, Aleksey Krylov

LOS ANGELES, June 24, 2021 /PRNewswire/ -- CytoImmune Therapeutics , a clinical-stage immunotherapy company developing a novel class of natural killer (NK) cell-based cancer therapies, today announce the appointment of Aleksey Krylov as Chief Financial Officer (CFO), effective as of April 14, 2021.

Key Points:

LOS ANGELES, June 24, 2021 /PRNewswire/ -- CytoImmune Therapeutics , a clinical-stage immunotherapy company developing a novel class of natural killer (NK) cell-based cancer therapies, today announce the appointment of Aleksey Krylov as Chief Financial Officer (CFO), effective as of April 14, 2021.
As the company advances human clinical trial programs in the latter half of 2021, Krylov will lead capital formation, investor relations, financial planning, accounting, financial reporting, control, tax, and treasury functions for CytoImmune.
"We welcome Aleksey to the executive team at a time of exceptional opportunity at CytoImmune and trust his experience in raising capital, taking companies public, and M&A will propel us forward," said Will Rosellini , President of CytoImmune.
Aleksey consulted with CytoImmune for nearly a year, so we expect a seamless transition to this full-time CFO role."

The Russian Direct Investment Fund : Sputnik V demonstrates 94.3% efficacy and high safety profile during the vaccination campaign in Bahrain

Retrieved on:

Thursday, June 10, 2021

COVID-19 pandemic in Russia, Articles, Finance, Money, Science and technology in Russia, Sputnik V COVID-19 vaccine, Russian Direct Investment Fund, COVID-19 vaccine, Sovereign wealth fund, Vaccination, Ministry of Health, Kirill Dmitriev

MOSCOW, June 10, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces thedata of the Ministry of Health of the Kingdom of Bahrain on the Russian Sputnik V coronavirus vaccine confirming its safety and high efficacy during the vaccination campaign in the country.

Key Points:

MOSCOW, June 10, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces thedata of the Ministry of Health of the Kingdom of Bahrain on the Russian Sputnik V coronavirus vaccine confirming its safety and high efficacy during the vaccination campaign in the country.
"Our data has confirmed the high efficacy and safety of Sputnik V during its use in Bahrain.
Sputnik V continues to play an important role in the Kingdom's ongoing and successful vaccination campaign, with 81% of the eligible population vaccinated so far."
Russian Direct Investment Fund (RDIF)is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors.

NASA Administrator Statement on Meeting with Roscosmos

Retrieved on:

Friday, June 4, 2021

Roscosmos, Science and technology in Russia, International Space Station, Dmitry Rogozin, Astronaut, Government, NASA, Spaceflight, Moscow

WASHINGTON, June 4, 2021 /PRNewswire/ -- NASA Administrator Bill Nelson released the following statement after an introductory call Friday with Roscosmos General Director Dmitry Rogozin:

Key Points:

WASHINGTON, June 4, 2021 /PRNewswire/ -- NASA Administrator Bill Nelson released the following statement after an introductory call Friday with Roscosmos General Director Dmitry Rogozin:
"I was pleased to speak with General Director Dimitry Rogozin this morning in a productive discussion about continued cooperation between NASA and Roscosmos.
"For more than 20 years, NASA astronauts and Roscosmos cosmonauts have lived and worked together on the International Space Station a success story that has yielded countless discoveries and enabled research not possible on Earth for the benefit of humanity.
NASA is committed to continuing that very effective ISS partnership.
For more information on NASA and agency activities, visit:
View original content to download multimedia: http://www.prnewswire.com/news-releases/nasa-administrator-statement-on-...

Sistema PJSFC: Binnopharm Group increases stake in Sintez to 88.6%

Retrieved on:

Wednesday, May 12, 2021

Russian Direct Investment Fund, Science and technology in Russia, Economy of Russia, Sputnik V COVID-19 vaccine, VTB Bank, MOEX, Economies, Companies

b'Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.\nThe issuer is solely responsible for the content of this announcement.\n12 May 2021, Moscow - Sistema PJSFC ("Sistema", the "Corporation" or, together with its subsidiaries and affiliates, the "Group") (LSE: SSA, MOEX: AFKS), a publicly traded Russian investment company, announces that its fully owned subsidiary LLC Sistema Telecom Assets has contributed its 32.4% stake in OJSC Sintez to the authorised capital of LLC Binnopharm Group.

Key Points:

b'Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.\nThe issuer is solely responsible for the content of this announcement.\n12 May 2021, Moscow - Sistema PJSFC ("Sistema", the "Corporation" or, together with its subsidiaries and affiliates, the "Group") (LSE: SSA, MOEX: AFKS), a publicly traded Russian investment company, announces that its fully owned subsidiary LLC Sistema Telecom Assets has contributed its 32.4% stake in OJSC Sintez to the authorised capital of LLC Binnopharm Group.
Following the transaction, Binnopharm Group has increased its stake in OJSC Sintez to 88.6%.\nAs a result, the effective stake in Binnopharm Group owned by Sistema together with VTB, Sistema\'s financial partner in the development of the pharmaceuticals business, now stands at 86.5%.
A consortium of investors consisting of the Russian Direct Investment Fund ("RDIF"), the Russia-China Investment Fund (co-founded by RDIF and China Investment Corporation) and leading Middle Eastern funds holds 12.5%, with the remaining 1% owned by a minority shareholder (an individual).\nBinnopharm Group is a full-cycle Russian pharmaceutical holding company that combines five production sites across Russia: JSC Alium (formerly OBL Pharm; Serpukhov district, Moscow region), JSC Binnopharm (two sites at Zelenograd and Krasnogorsk), JSC\xc2\xa0Sintez (Kurgan) and JSC Biocom (Stavropol).
Binnopharm Group companies produce a wide range of drugs in various therapeutic groups and have the largest portfolio of drugs among Russian manufacturers with more than 450 marketing authorisations, including the COVID-19 vaccine Sputnik V.\nFor further information, please visit www.sistema.ru or contact:\n'

RDIF: Production of Sputnik V launched in Argentina

Retrieved on:

Tuesday, April 20, 2021

COVID-19 pandemic in Russia, Science and technology in Russia, Sputnik V COVID-19 vaccine, Mass media, Kirill Dmitriev, Medicine, Articles, Russian Direct Investment Fund, Sputnik

"\nKirill Dmitriev, CEO of the Russian Direct Investment Fund, said:\n"Argentina was the first country of Latin America to approve Sputnik V and begin using it to vaccinate the population.

Key Points:

"\nKirill Dmitriev, CEO of the Russian Direct Investment Fund, said:\n"Argentina was the first country of Latin America to approve Sputnik V and begin using it to vaccinate the population.
Today we are delighted to announce that Argentina has become the first country of the region to launch the production of Sputnik V thanks to parthership between RDIF and Laboratorios Richmond.
Sputnik V is approved in more than 10 countries of Latin and Central America and production in Argentina will help facilitate deliveries to other partners in the region.
"\n"Laboratories Richmond is proud to have the support of the Russian Direct Investment Fund that relied on our scientific and technical platform to produce the Sputnik V vaccine in Argentina.

Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India

Retrieved on:

Tuesday, April 13, 2021

Biotechnology, Pharmaceutical, Health, Clinical trials, Adenoviridae, COVID-19 vaccines, Clinical trials, COVID-19 pandemic in Russia, Science and technology in Russia, Sputnik V COVID-19 vaccine, Vaccination, Dr. Reddy's Laboratories, Articles, Life sciences, Medicine

Phase II / III clinical trials of the vaccine were carried out by Dr. Reddy\xe2\x80\x99s in India.\nDr Reddy\xe2\x80\x99s Laboratories co-chairman and managing director GV Prasad said, \xe2\x80\x9cWe are very pleased to obtain the emergency use authorisation for Sputnik V in India.

Key Points:

Phase II / III clinical trials of the vaccine were carried out by Dr. Reddy\xe2\x80\x99s in India.\nDr Reddy\xe2\x80\x99s Laboratories co-chairman and managing director GV Prasad said, \xe2\x80\x9cWe are very pleased to obtain the emergency use authorisation for Sputnik V in India.
With the rising cases in India, vaccination is the most effective tool in our battle against COVID-19.
Sputnik V uses two different vectors for the two shots in a course of vaccination.
The company assumes no obligation to update any information contained herein.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210412006057/en/\n'